Sign up to save your podcasts
Or
Share DeLLphi-301 - FDA Approval of Tarlatamab in Patients w/ Prev Treated Small Cell Lung Cancer (SCLC)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
DeLLphi-301 - FDA Approval of Tarlatamab in Patients w/ Prev Treated Small Cell Lung Cancer (SCLC)
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:
• The study's primary endpoint of objective response rate and its implications for patient care.
• The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells.
• The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
• Strategies for community oncologists to effectively manage patients receiving this new treatment.
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:
• The study's primary endpoint of objective response rate and its implications for patient care.
• The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells.
• The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
• Strategies for community oncologists to effectively manage patients receiving this new treatment.
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
288 Listeners
White Coat Investor Podcast
2,435 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
The ONS Podcast
199 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Two Onc Docs
185 Listeners